I tend to jump to this section these days - Unfortunately think we might need to raise next year even with R&D rebate, If we wish to retain a buffer. I hope we wait to mid 2024 when armed with interim efficacy readouts. Hoping next cap raise will be much higher than the last 17c raise.
They’ve started historical studies with 1 patient finished screening. Not much new news, sadly delay of key clinic milestones, now confirmed to be shifted right to early next year due to IND being Q4; not sure if approval expected then too.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.050(4.35%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.21 | $1.13 | $387.7K | 327.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 25000 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |